KM Research Hub
← 返回结果库查看论文详情PubMed ↗
READ-ONLY DIGITIZATION RESULT

Toripalimab Plus Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Lung Cancer: The Phase 3 EXTENTORCH Randomized Clinical Trial.

JAMA Oncol · 2025-Jan-01 · PMID 39541202

Panel B提取完成待 EXE 对齐验证

overall survival

Figure 3.. Biomarker Analysis A and B, The associations of intratumor heterogeneity (ITH) with progression-free survival (PFS) and overall survival (OS) are shown. Patients with ITH-low tumors, as defined by a Mutant-Allele Tumor Heterogeneity score of less than 29, achieved significantly better PFS and OS from toripalimab plus chemotherapy. C and D, Kaplan-Meier–estimated PFS and OS curves compare the toripalimab plus chemotherapy group with the placebo plus chemotherapy group between HLA-A11 + HLA-B62 − and HLA-A11 − HLA-B62 + / HLA-A11 + HLA-B62 + / HLA-A11 − HLA-B62 − subgroups. Patients with HLA-A11 + HLA-B62 − haplotype had more favorable outcomes from toripalimab plus chemotherapy. The P for interaction values of the subgroup variables were computed using the Cox proportional hazards regression model. NR indicates not reached.

算法:legacy-0.5.0引擎:enhanced-linux
质量评分1.00
质量通过是
预期曲线4
实际曲线4
X 范围-
Y 范围-

曲线数据

网页最多预览 200 行,完整数据请下载 CSV 或 JSON。

当前面板没有可预览的 `curves_mapped.csv` 数据。
历史版本(1)

重跑只新增版本,不覆盖旧结果;正式可用状态仅授予通过 EXE 基准或人工复核的版本。

版本状态验证曲线时间
legacy-0.5.0complete待验证42026-07-23T18:22:52+00:00